These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23666046)

  • 1. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.
    Tenembaum SN; Banwell B; Pohl D; Krupp LB; Boyko A; Meinel M; Lehr L; Rocak S; Cantogno EV; Moraga MS; Ghezzi A;
    J Child Neurol; 2013 Jul; 28(7):849-56. PubMed ID: 23666046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.
    Tenembaum SN; Segura MJ
    Neurology; 2006 Aug; 67(3):511-3. PubMed ID: 16775230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
    Krupp LB; Pohl D; Ghezzi A; Boyko A; Tenembaum S; Chen L; Aycardi E; Banwell B;
    J Neurol Sci; 2016 Apr; 363():33-8. PubMed ID: 27000217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.
    Pohl D; Rostasy K; Gärtner J; Hanefeld F
    Neurology; 2005 Mar; 64(5):888-90. PubMed ID: 15753430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1a in children with multiple sclerosis is well tolerated.
    Waubant E; Hietpas J; Stewart T; Dyme Z; Herbert J; Lacy J; Miller C; Rensel M; Schwid S; Goodkin D
    Neuropediatrics; 2001 Aug; 32(4):211-3. PubMed ID: 11571702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
    Bermel RA; Weinstock-Guttman B; Bourdette D; Foulds P; You X; Rudick RA
    Mult Scler; 2010 May; 16(5):588-96. PubMed ID: 20167591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.
    Francis GS; Grumser Y; Alteri E; Micaleff A; O'Brien F; Alsop J; Stam Moraga M; Kaplowitz N
    Drug Saf; 2003; 26(11):815-27. PubMed ID: 12908850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
    Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
    Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.